Clinical Trial Update: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 global trial evaluating durvalumab alone or with tremelimumab versus standard of care in locally advanced or metastatic non-small cell lung cancer, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non - Small Cell Lung Cancer NSCLC | Phase 3 | Status: COMPLETED | Results posted: 2019-04-16